Table 4.

IGFBP transgenic and KO mouse lines

Mouse lines		Discovery (Year/Lab/first)	Expression control	Serum GH	Serum IGF1	Size / weight	Body composition	Insulin sensitivity	Reproductive capacity	Cancer incidence	Lifespan	Original references
IGFBP1	human IGFBP1 transgene	1995 Dai (D'Ercole)	mouse Mt1	n/a	n/a	↓ weight	not consistent	↓	↓ ♀	n/a	n/a	[312]
	IGFBP1 KO	2003 Taub (Leu)	NeoR replacement of promotor and exons 1–2	n/a	↑ before 4 mo	–	n/a	–	n/a	↓ prostate tumor size; ↓ proliferation, but not incidence	n/a	[318]
IGFBP2	IGFBP2 transgene	1999 Wolf (Hoeflich)	CMV	–	–	–	↑ fat	↑ sensitivity; ↓ serum insulin	n/a	↓ colorectal tumor growth with induced carcinogenesis	n/a	[320]
	IGFBP2 KO	2000 Pintar (Wood)	NeoR replacement of exon 3	–	–	–weight;↑L; ↓S,H,K	n/a	–	–	n/a	n/a	[323]
IGFBP3	human IGFBP3 transgene	1995 Molnar (Murphy)	mouse Mt1	n/a	n/a	↑ S,L,H	↑ fat	n/a	–	n/a	n/a	[325]
	IGFBP3 KO	2006 Pintar (Ning)	NeoR replacement of exon1-3	n/a	n/a	↑ weight until 22 wk; – afterward	–	–; impaired glucose homeostasis on HFD	n/a	↑ lung cancer tumorigenesis	n/a	[328]
IGFBP4	IGFBP4 transgene	1998 Fagin (Wang)	murine cDNA driven by α-actin	n/a	n/a	↓ thymus	n/a	n/a	n/a	n/a	n/a	[331]
	IGFBP4 KO	2006 Pintar (Ning)	NeoR replacement of exon1	n/a	–	↓	↓ fat, femur length	n/a	–	n/a	n/a	[328]
IGFBP5	IGFBP5 transgene	2002 Flint (Tonner)	β-lactoglobulin	n/a	↑	↓ weight	↓ lean	n/a	↓ fertility ♀	n/a	↑ neonatal mortality	[335]
	IGFBP5 KO	2006 Pintar (Ning)	NeoR replacement of exon1	n/a	–	–	↑ fat	mild glucose intolerance	–	n/a	n/a	[328]
IGFBP6	IGFBP6 transgene	2004 Babajko (Bienvenu)	glial fibrillary acidic protein promoter/enhancer	n/a	↓ 15 d; – 1, 3 mo	↓ weight; growth retardation up to 3 mo	n/a	mild insulin resistance w/ diet-induced obesity	↓	n/a	n/a	[340]

“—” indicates no changes; n/a indicates not available; “d” indicates days of age, “wk” indicates weeks of age, “mo” indicates months of age; ♀ indicates female. K, kidney, L, liver, S, spleen, H, heart